Abstract Body

Background: Inflammatory markers are increased in untreated HIV infected individuals and, as immune activation, are not normalized by combination antiretroviral therapy (cART). Long term (48 weeks) intensification of cART with Raltegravir reduced CD8 T-cell activation in the Discorral and IntegRal studies. Therefore, we have evaluated the effect of Raltegravir intensification in several soluble plasma markers in these studies. Methodology: Longitudinal plasma samples (0-48 weeks) from the Integral (67 individuals with high CD4 T-cell counts, 22 control and 45 intensified individuals) and the DiscorRal studies (44 individuals with CD4 T-cell counts >350 cells/μl, 14 control and 30 intensified individuals) were analyzed using a BioRad Multiplexed cytokine array covering 22 markers. Mann-Whitney, Wilcoxon and Spearman tests were used for analysis. Results: Before intensification, individuals enrolled in the Discorral Study (median CD4 T-cell counts 248 cells/μL) showed a significant higher level of most inflammatory cytokines when compared with individuals enrolled in the IntegRal study, which had a median CD4 T-cell counts of 520 cells/μL. Main differences were observed in pro-inflammatory cytokines IP10 (p=0.001), IL-1b (p=0.0006), IL-12 (p=0.006), IL-13 (p=0.0001), IL-17 (p=0.0084) and TNFa (p=0.0024), apoptosis mediators such as TRAIL (p=0.0024) or homeostatic cytokines as IL-7 (p=0.0009). Consistently, significant negative correlations between most of these markers and CD4 T-cell counts were found: IP10 (r2=0.074), TRAIL (r2=0.074), IL-17 (r2=0.064), IL-1b (r2=0.06) and IL-13 (r2=0.06), p<0.02 in all cases. Moreover, a marker of endothelial function, sVCAM-1, was negatively correlated with CD4 T-cell counts (r2=0.06, p=0.009). Longitudinal analysis showed that 48-week raltegravir intensification failed to induce significant changes in cytokine levels in individuals with high CD4 T-cells (IntegRal study) although significantly reduced some of the cytokines increased in individuals with low CD4 T-cell counts (Discorral study) at week 48, especially IP10 (p=0.03) and a trend was observed with TNFa (p=0.09). Conclusions: Inflammatory profile is strongly associated with the level of CD4 T-cells in long term cART treated HIV infected individuals. Raltegravir intensification has little effect on these markers, although a positive impact could be observed in individuals with poor CD4 T-cell recovery.